Wade Berry

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

Suresh S. Ramalingam, Jeffrey Crawford, Alex Y. Chang et al. · Annals of Oncology · 2013 · 55 citations

Antifibrotic Therapy, Fortis-m Trial, Medicine +9

Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study

Khoan Vu, Chi-Heng Wu, Chen‐Yen Yang et al. · Clinical Cancer Research · 2019 · 38 citations · Full text

AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.

John D. Powderly, Paul L. de Souza, Rodolfo Gutierrez et al. · Journal of Clinical Oncology · 2019 · 32 citations

Adenosine Receptor Coverage, Pharmacotherapy, Tumor Biology +17

ARC-8: Phase I/Ib study to evaluate safety and tolerability of AB680 + chemotherapy + zimberelimab (AB122) in patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC).

Gulam A. Manji, Zev A. Wainberg, Kartik Krishnan et al. · Journal of Clinical Oncology · 2021 · 26 citations

Immunology, Pathology, Cell Death +22

MASS SCREENING FOR CANCER OF THE BREAST

Stephen L. Barnes, Wade Berry, Marc Williams et al. · The Lancet · 1968 · 18 citations

Breast Oncology, Cancer Screening, Medicine +5